|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SNUPN |
Gene summary for SNUPN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SNUPN | Gene ID | 10073 |
| Gene name | snurportin 1 | |
| Gene Alias | KPNBL | |
| Cytomap | 15q24.2 | |
| Gene Type | protein-coding | GO ID | GO:0006403 | UniProtAcc | O95149 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10073 | SNUPN | LZE2T | Human | Esophagus | ESCC | 4.88e-02 | 3.13e-01 | 0.082 |
| 10073 | SNUPN | LZE4T | Human | Esophagus | ESCC | 1.31e-09 | 1.73e-01 | 0.0811 |
| 10073 | SNUPN | LZE7T | Human | Esophagus | ESCC | 9.37e-07 | 3.65e-01 | 0.0667 |
| 10073 | SNUPN | LZE8T | Human | Esophagus | ESCC | 7.28e-06 | 1.62e-01 | 0.067 |
| 10073 | SNUPN | LZE20T | Human | Esophagus | ESCC | 6.07e-05 | 1.04e-01 | 0.0662 |
| 10073 | SNUPN | LZE24T | Human | Esophagus | ESCC | 5.87e-07 | 1.63e-01 | 0.0596 |
| 10073 | SNUPN | LZE6T | Human | Esophagus | ESCC | 5.53e-04 | 3.33e-01 | 0.0845 |
| 10073 | SNUPN | P1T-E | Human | Esophagus | ESCC | 4.30e-08 | 3.49e-01 | 0.0875 |
| 10073 | SNUPN | P2T-E | Human | Esophagus | ESCC | 7.96e-19 | 2.21e-01 | 0.1177 |
| 10073 | SNUPN | P4T-E | Human | Esophagus | ESCC | 7.83e-23 | 6.28e-01 | 0.1323 |
| 10073 | SNUPN | P5T-E | Human | Esophagus | ESCC | 9.39e-11 | 1.94e-01 | 0.1327 |
| 10073 | SNUPN | P8T-E | Human | Esophagus | ESCC | 1.30e-18 | 2.89e-01 | 0.0889 |
| 10073 | SNUPN | P9T-E | Human | Esophagus | ESCC | 1.06e-25 | 6.66e-01 | 0.1131 |
| 10073 | SNUPN | P10T-E | Human | Esophagus | ESCC | 1.73e-35 | 5.55e-01 | 0.116 |
| 10073 | SNUPN | P11T-E | Human | Esophagus | ESCC | 1.68e-07 | 2.02e-01 | 0.1426 |
| 10073 | SNUPN | P12T-E | Human | Esophagus | ESCC | 1.05e-20 | 3.88e-01 | 0.1122 |
| 10073 | SNUPN | P15T-E | Human | Esophagus | ESCC | 3.08e-29 | 5.46e-01 | 0.1149 |
| 10073 | SNUPN | P16T-E | Human | Esophagus | ESCC | 3.79e-40 | 7.03e-01 | 0.1153 |
| 10073 | SNUPN | P17T-E | Human | Esophagus | ESCC | 1.05e-08 | 2.35e-01 | 0.1278 |
| 10073 | SNUPN | P19T-E | Human | Esophagus | ESCC | 1.17e-08 | 6.72e-01 | 0.1662 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001593111 | Liver | HCC | nucleobase-containing compound transport | 150/7958 | 222/18723 | 3.17e-14 | 2.03e-12 | 150 |
| GO:001703811 | Liver | HCC | protein import | 140/7958 | 206/18723 | 1.12e-13 | 6.46e-12 | 140 |
| GO:005117011 | Liver | HCC | import into nucleus | 102/7958 | 159/18723 | 2.78e-08 | 6.39e-07 | 102 |
| GO:00066066 | Liver | HCC | protein import into nucleus | 99/7958 | 155/18723 | 6.12e-08 | 1.28e-06 | 99 |
| GO:007259418 | Oral cavity | OSCC | establishment of protein localization to organelle | 284/7305 | 422/18723 | 1.50e-32 | 1.35e-29 | 284 |
| GO:000640318 | Oral cavity | OSCC | RNA localization | 150/7305 | 201/18723 | 6.90e-25 | 1.98e-22 | 150 |
| GO:000691317 | Oral cavity | OSCC | nucleocytoplasmic transport | 204/7305 | 301/18723 | 2.65e-24 | 6.98e-22 | 204 |
| GO:005116917 | Oral cavity | OSCC | nuclear transport | 204/7305 | 301/18723 | 2.65e-24 | 6.98e-22 | 204 |
| GO:003450415 | Oral cavity | OSCC | protein localization to nucleus | 193/7305 | 290/18723 | 1.22e-21 | 2.35e-19 | 193 |
| GO:005065714 | Oral cavity | OSCC | nucleic acid transport | 120/7305 | 163/18723 | 2.31e-19 | 3.18e-17 | 120 |
| GO:005065814 | Oral cavity | OSCC | RNA transport | 120/7305 | 163/18723 | 2.31e-19 | 3.18e-17 | 120 |
| GO:005123614 | Oral cavity | OSCC | establishment of RNA localization | 121/7305 | 166/18723 | 6.38e-19 | 8.24e-17 | 121 |
| GO:001593114 | Oral cavity | OSCC | nucleobase-containing compound transport | 150/7305 | 222/18723 | 4.86e-18 | 5.04e-16 | 150 |
| GO:001703815 | Oral cavity | OSCC | protein import | 136/7305 | 206/18723 | 3.15e-15 | 2.08e-13 | 136 |
| GO:00511709 | Oral cavity | OSCC | import into nucleus | 100/7305 | 159/18723 | 8.67e-10 | 2.15e-08 | 100 |
| GO:00066069 | Oral cavity | OSCC | protein import into nucleus | 97/7305 | 155/18723 | 2.27e-09 | 5.30e-08 | 97 |
| GO:007259419 | Oral cavity | LP | establishment of protein localization to organelle | 205/4623 | 422/18723 | 6.76e-27 | 3.85e-24 | 205 |
| GO:000640319 | Oral cavity | LP | RNA localization | 105/4623 | 201/18723 | 3.34e-17 | 5.36e-15 | 105 |
| GO:003450416 | Oral cavity | LP | protein localization to nucleus | 133/4623 | 290/18723 | 2.41e-15 | 3.35e-13 | 133 |
| GO:000691318 | Oral cavity | LP | nucleocytoplasmic transport | 130/4623 | 301/18723 | 1.19e-12 | 9.77e-11 | 130 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301321 | Esophagus | ESCC | Nucleocytoplasmic transport | 89/4205 | 108/8465 | 1.20e-12 | 2.37e-11 | 1.21e-11 | 89 |
| hsa0301331 | Esophagus | ESCC | Nucleocytoplasmic transport | 89/4205 | 108/8465 | 1.20e-12 | 2.37e-11 | 1.21e-11 | 89 |
| hsa03013 | Liver | HCC | Nucleocytoplasmic transport | 81/4020 | 108/8465 | 4.28e-09 | 6.83e-08 | 3.80e-08 | 81 |
| hsa030131 | Liver | HCC | Nucleocytoplasmic transport | 81/4020 | 108/8465 | 4.28e-09 | 6.83e-08 | 3.80e-08 | 81 |
| hsa030136 | Oral cavity | OSCC | Nucleocytoplasmic transport | 82/3704 | 108/8465 | 7.93e-12 | 1.33e-10 | 6.77e-11 | 82 |
| hsa0301311 | Oral cavity | OSCC | Nucleocytoplasmic transport | 82/3704 | 108/8465 | 7.93e-12 | 1.33e-10 | 6.77e-11 | 82 |
| hsa030132 | Oral cavity | LP | Nucleocytoplasmic transport | 53/2418 | 108/8465 | 4.68e-06 | 4.10e-05 | 2.64e-05 | 53 |
| hsa030133 | Oral cavity | LP | Nucleocytoplasmic transport | 53/2418 | 108/8465 | 4.68e-06 | 4.10e-05 | 2.64e-05 | 53 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SNUPN | SNV | Missense_Mutation | rs779696140 | c.128N>A | p.Arg43His | p.R43H | O95149 | protein_coding | deleterious(0) | probably_damaging(0.963) | TCGA-AC-A3W7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| SNUPN | SNV | Missense_Mutation | c.274A>G | p.Lys92Glu | p.K92E | O95149 | protein_coding | deleterious(0.03) | benign(0.175) | TCGA-BH-A18R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SNUPN | SNV | Missense_Mutation | c.658N>A | p.Glu220Lys | p.E220K | O95149 | protein_coding | tolerated(0.07) | benign(0.071) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
| SNUPN | SNV | Missense_Mutation | novel | c.1034N>T | p.Lys345Met | p.K345M | O95149 | protein_coding | tolerated_low_confidence(0.07) | benign(0.068) | TCGA-JL-A3YW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SNUPN | SNV | Missense_Mutation | novel | c.1008G>T | p.Leu336Phe | p.L336F | O95149 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.998) | TCGA-UU-A93S-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| SNUPN | SNV | Missense_Mutation | rs377184433 | c.367G>A | p.Val123Met | p.V123M | O95149 | protein_coding | deleterious(0.05) | possibly_damaging(0.576) | TCGA-AA-3846-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SNUPN | SNV | Missense_Mutation | rs142962123 | c.718N>A | p.Glu240Lys | p.E240K | O95149 | protein_coding | deleterious(0.04) | benign(0.006) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| SNUPN | SNV | Missense_Mutation | c.922N>A | p.Gln308Lys | p.Q308K | O95149 | protein_coding | deleterious(0.04) | probably_damaging(0.96) | TCGA-EI-7004-01 | Colorectum | rectum adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | SD | |
| SNUPN | SNV | Missense_Mutation | rs142962123 | c.718N>A | p.Glu240Lys | p.E240K | O95149 | protein_coding | deleterious(0.04) | benign(0.006) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SNUPN | SNV | Missense_Mutation | novel | c.114N>T | p.Leu38Phe | p.L38F | O95149 | protein_coding | tolerated(0.37) | probably_damaging(0.965) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |